Endostar Treatment of Advanced Non-small Cell Lung Cancer Multi-center Clinical Research
NCT ID: NCT02513355
Last Updated: 2015-08-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
400 participants
INTERVENTIONAL
2015-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Degree of continuous intravenous pumping Endostar (human recombinant endostatin) combination chemotherapy regimens including cisplatin two medicine first-line treatment of advanced non-small cell lung cancer (with the exception of EGFR/ALK mutations) efficacy and safety.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Endostar Combination With Chemotherapy and EGFR-TKI in Lung Cancer Rechallenging Treatment After Acquired Resistance.
NCT02350361
First-Line Treatment of Advanced Non-Small-Cell Lung Cancer With Negative Driver Gene: a Multicenter, Single-Arm Trial
NCT05574998
Rh-endostatin Combined With Chemotherapy and Pembrolizumab for Advanced NSCLC
NCT04094909
Endostar Plus EGFR-TKI（Epidermal Growth Factor Receptor-Tyrosine-Kinase Inhibitor） as a Treatment of EGFR Mutation-positive NSCLC
NCT03008109
Rh-Endostatin in Combination With Icotinib for Advanced NSCLC With EGFR Mutations
NCT02375022
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
2.1 main objectives: PFS 2.2 the secondary goal: 2.2. 1 ORR, DCR and OS 2.2. 2 the quality of life 3. The study design 3.1 research nature This is a single arm, multicenter clinical study, is expected to total 100 patients into the group.
Hierarchical factors include: the tumor staging (Ⅲ B vs Ⅳ), ECOG score (0 v 1), gender (male vs female).
3.2 research center and research Proposed by taizhou people's hospital and medical association of jiangsu province tumor chemotherapy and biological branch of the lung cancer group led by several large and medium-sized hospitals in the province of the malignant tumor treatment related department to participate, in accordance with the unified test plan of this research.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
NP(Changchun marina+cisplatin)+Endostar
Patients in this group will be given conventional chemotherapy medicine,NP plan (Changchun marina+cisplatin)recommended by treatment guidelines for Advanced non small cell lung cancer. Endostar 15mg/m2, 21 days per cycle, 4 to 6 cycles;Changchun marina;25mg/m2,d1 and d8,cisplatin 80mg/m2,d1, q21d×4
Endostar
Endostar 15mg/m2, 21 days per cycle, 4 to 6 cycles
Changchun marina
25mg/m2,d1 and d8,q21d×4
cisplatin
80mg/m2,d1, q21d×4
TP(Taxol+cisplatin or parapl) +Endostar
Patients in this group will be given conventional chemotherapy medicine,TP(Taxol+cisplatin)recommended by treatment guidelines for Advanced non small cell lung cancer.
Endostar 15mg/m2, 21 days per cycle, 4 to 6 cycles; Taxol;135-175mg/m2,d1,cisplatin or parapl 75mg/m2,d1,q21d×4.
Endostar
Endostar 15mg/m2, 21 days per cycle, 4 to 6 cycles
cisplatin
80mg/m2,d1, q21d×4
Taxol
135-175mg/m2,d1,q21d×4
parapl
AUC=5-6,d1,q21d×4
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Endostar
Endostar 15mg/m2, 21 days per cycle, 4 to 6 cycles
Changchun marina
25mg/m2,d1 and d8,q21d×4
cisplatin
80mg/m2,d1, q21d×4
Taxol
135-175mg/m2,d1,q21d×4
parapl
AUC=5-6,d1,q21d×4
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* according to a new IASLC2009 lung cancer TNM stages judged the preious untreated stage IIIB or IV non-small cell lung cancer (with the exception of EGFR/ALK mutations type);
* must have at least one according to the RRECIST version 1.1 standard judgment to evaluate lesions (at least 10 mm, maximum diameter on spiral CT plain CT longest diameter at least 20 mm);
* male or female, age 18 and 75 years old or less or more;
* ECOG PS 0 \~ 1 minute;
* is expected to survive period for 3 months or more,
* enough blood function: absolute neutrophil count (ANC) or 2 x 109 / L and the platelet count 100 x 109 / L or higher acuity 9 g/dL and hemoglobin;
* Liver function enough: upper limit of total bilirubin acuities were normal (ULN); AST and ALT acuities were 2.5 times the upper limit of normal (ULN); Alkaline phosphatase 5 times the upper limit of normal or less (ULN);
* enough renal function, serum creatinine or less normal limit (ULN) or calculated creatinine clearance or 60 mL/min.
* basic normal ecg, had on the body to heal wounds;
* always not received anti-tumor drug therapy, or always only for non metastatic tumor of adjuvant or neoadjuvant chemotherapy, but to study treatment has ended more than six months at the beginning;
* ever had had surgery patients, request to study treatment began to have more than 4 weeks, and the patient has recovered;
* a complete uterus of female in the group within 28 days before the study must have a negative pregnancy test results (except amenorrhea has 24 months). If the pregnancy test from the first time for more than 7 days, is the need for urine pregnancy test validation (within 7 days before the first delivery).
* prior to biological agents, especially e. coli genetically engineered products without severe allergic reactions;
* signed informed consent.
Exclusion Criteria
* the existing serious acute infection, and not be controlled; Or fester sex and chronic infection, wound in delay no more;
* the original serious heart disease, including: higher risk of congestive heart failure, unable to control arrhythmia, unstable angina, myocardial infarction, severe valvular heart disease, and resistant hypertension;
* is not easy to control nerve, mental illness or mental disorders, compliance is poor, can't cooperate with accounts and response to treatment; Primary brain tumors or CNS metastases illness did not get a control, has obvious symptoms in cranial hypertension or nerve spirit;
* with bleeding tendency;
* other researchers believe that patients should not participate in this test.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Nanjing NingQi Medicine Science and Technology Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Han gaohua, PI
Role: STUDY_CHAIR
China:Taizhou people's hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Jiangsu Taizhou People's Hospital
Nanjing, Jiangsu, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
JS-ENDO-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.